Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 14, 2026 21:00 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Exercise / conversionRestricted Stock Units · Derivative | 272,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-006493 · ownership.xml · derivative · entry 7 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 272,056 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vested on August 14, 2026. F5 · derivative.expiration_date: 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vested on August 14, 2026. Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:00 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Tax withholdingCommon Stock | 120,521 | $1.01 | $121,726.21 |
DisclosureSEC source: 0001683168-26-006493 · ownership.xml · nonDerivative · entry 2 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,716 F1 · shares: Represents 120,521 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs"). F2 · price: Represents the closing price of Issuer's common stock on August 14, 2026. F1 · balance_after: Represents 120,521 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs"). Read SEC document |
| August 14, 2026 Filed Aug 14, 2026 21:00 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Exercise / conversionCommon Stock | 272,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-006493 · ownership.xml · nonDerivative · entry 1 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the issuance of 272,056 shares of common stock from the vesting and settlement of 272,056 RSUs, which number excludes the withholding of 120,521 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1). F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · balance_after: Represents the issuance of 272,056 shares of common stock from the vesting and settlement of 272,056 RSUs, which number excludes the withholding of 120,521 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1). Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:10 UTC |
Sawhney RogerDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004255 · ownership.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:15 UTC |
Zabrowski DanDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004260 · ownership.xml · derivative · entry 1 Zabrowski Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:14 UTC |
THOMSON TODD SDirector · 10% owner
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004257 · ownership.xml · derivative · entry 1 THOMSON TODD S · CIK 0001225707 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F2 · kind: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4. F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. F2 · ownership.direct: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:09 UTC |
RONNEBERG AMY LDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004251 · ownership.xml · derivative · entry 1 RONNEBERG AMY L · CIK 0001380292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:04 UTC |
Keyes Jason ADirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004245 · ownership.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:03 UTC |
Huber Martin H. Jr.Director
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004243 · ownership.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:02 UTC |
Fletcher Aaron G.L.Director · 10% owner
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004241 · ownership.xml · derivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 21:19 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 237,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001683168-26-002582 · ownership.xml · derivative · entry 1 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,000 Underlying: Common Stock · 237,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 21:19 UTC |
Mazar Andrew PaulChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001683168-26-002581 · ownership.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 21:19 UTC |
LYTLE PAUL JChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001683168-26-002580 · ownership.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 23:10 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Exercise / conversionRestricted Stock Units · Derivative | 272,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-001039 · ownership.xml · derivative · entry 7 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,056 Underlying: Common Stock · 272,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026. F5 · derivative.expiration_date: 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026. Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 23:10 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Tax withholdingCommon Stock | 121,874 | $4.33 | $527,714.42 |
DisclosureSEC source: 0001683168-26-001039 · ownership.xml · nonDerivative · entry 2 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,181 F1 · shares: Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs"). F2 · price: Represents the closing price of Issuer's common stock on February 13, 2026. F1 · balance_after: Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs"). Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 23:10 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
Exercise / conversionCommon Stock | 272,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-001039 · ownership.xml · nonDerivative · entry 1 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1). F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · balance_after: Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1). Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 17:45 UTC |
THOMSON TODD SDirector · 10% owner
Kairos Venture Partners II, L.P.Director · 10% owner
|
SaleCommon Stock | 280,000 | $5.80 | $1,624,000.00 |
DisclosureSEC source: 0001011438-26-000005 · form4.xml · nonDerivative · entry 1 THOMSON TODD S · CIK 0001225707 · Director · 10% owner Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Kairos Venture Partners II, L.P. Disclosed balance after: 904,795 F1 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI. F2 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purpose. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:01 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
PurchaseWarrant (Right to Buy) · Derivative | 71,428 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-063991 · tm2519406-2_4seq1.xml · derivative · entry 19 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 71,428 Underlying: Common Stock · 71,428 shares Expires not disclosed F2 · kind: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.exercise_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.expiration_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:01 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
PurchaseCommon Stock | 71,428 | $7.00 | $499,996.00 |
DisclosureSEC source: 0001104659-25-063991 · tm2519406-2_4seq1.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 196,428 F1 · kind: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the "Issuer") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the "Common Stock"), and warrants to purchase 71,428 shares of Common Stock (the "Warrants"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:03 UTC |
Bios Equity COF, LPDirector · 10% owner
Bios Clinical Opportunity Fund, LPDirector · 10% owner
Bios 2024 Co-Invest, LPDirector · 10% owner
BP Directors, LPDirector · 10% owner
|
PurchaseWarrant (Right to Buy) · Derivative | 71,428 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-063993 · tm2519406-1_4seq1.xml · derivative · entry 19 Bios Equity COF, LP · CIK 0002000747 · Director · 10% owner Bios Clinical Opportunity Fund, LP · CIK 0001988639 · Director · 10% owner Bios 2024 Co-Invest, LP · CIK 0002028708 · Director · 10% owner BP Directors, LP · CIK 0001813311 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 71,428 Underlying: Common Stock · 71,428 shares Expires not disclosed F2 · kind: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.exercise_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.expiration_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:03 UTC |
Bios Equity COF, LPDirector · 10% owner
Bios Clinical Opportunity Fund, LPDirector · 10% owner
Bios 2024 Co-Invest, LPDirector · 10% owner
BP Directors, LPDirector · 10% owner
|
PurchaseCommon Stock | 71,428 | $7.00 | $499,996.00 |
DisclosureSEC source: 0001104659-25-063993 · tm2519406-1_4seq1.xml · nonDerivative · entry 1 Bios Equity COF, LP · CIK 0002000747 · Director · 10% owner Bios Clinical Opportunity Fund, LP · CIK 0001988639 · Director · 10% owner Bios 2024 Co-Invest, LP · CIK 0002028708 · Director · 10% owner BP Directors, LP · CIK 0001813311 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 196,428 F1 · kind: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the "Issuer") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the "Common Stock"), and warrants to purchase 71,428 shares of Common Stock (the "Warrants"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:02 UTC |
Kreis Leslie W.Director · 10% owner
Cavu Advisors, LLCDirector · 10% owner
Cavu Management, LPDirector · 10% owner
BIOS Fund I, LPDirector · 10% owner
BIOS Fund I QP, LPDirector · 10% owner
Bios Equity Partners, LPDirector · 10% owner
BIOS Fund II, LPDirector · 10% owner
BIOS Fund II NT, LPDirector · 10% owner
BIOS Fund II QP, LPDirector · 10% owner
Bios Equity Partners II, LPDirector · 10% owner
|
PurchaseWarrant (Right to Buy) · Derivative | 71,428 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-063992 · tm2519406-3_4seq1.xml · derivative · entry 19 Kreis Leslie W. · CIK 0001813316 · Director · 10% owner Cavu Advisors, LLC · CIK 0001813310 · Director · 10% owner Cavu Management, LP · CIK 0001813270 · Director · 10% owner BIOS Fund I, LP · CIK 0001697316 · Director · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · Director · 10% owner Bios Equity Partners, LP · CIK 0001813314 · Director · 10% owner BIOS Fund II, LP · CIK 0001714576 · Director · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · Director · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · Director · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 71,428 Underlying: Common Stock · 71,428 shares Expires not disclosed F2 · kind: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.exercise_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F2 · derivative.expiration_date: The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration ("FDA") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: (Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: (Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 13:02 UTC |
Kreis Leslie W.Director · 10% owner
Cavu Advisors, LLCDirector · 10% owner
Cavu Management, LPDirector · 10% owner
BIOS Fund I, LPDirector · 10% owner
BIOS Fund I QP, LPDirector · 10% owner
Bios Equity Partners, LPDirector · 10% owner
BIOS Fund II, LPDirector · 10% owner
BIOS Fund II NT, LPDirector · 10% owner
BIOS Fund II QP, LPDirector · 10% owner
Bios Equity Partners II, LPDirector · 10% owner
|
PurchaseCommon Stock | 71,428 | $7.00 | $499,996.00 |
DisclosureSEC source: 0001104659-25-063992 · tm2519406-3_4seq1.xml · nonDerivative · entry 1 Kreis Leslie W. · CIK 0001813316 · Director · 10% owner Cavu Advisors, LLC · CIK 0001813310 · Director · 10% owner Cavu Management, LP · CIK 0001813270 · Director · 10% owner BIOS Fund I, LP · CIK 0001697316 · Director · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · Director · 10% owner Bios Equity Partners, LP · CIK 0001813314 · Director · 10% owner BIOS Fund II, LP · CIK 0001714576 · Director · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · Director · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · Director · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios 2024 Co-Invest, LP Disclosed balance after: 196,428 F1 · kind: Pursuant to a Securities Purchase Agreement (the "Securities Purchase Agreement"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the "Issuer") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the "Common Stock"), and warrants to purchase 71,428 shares of Common Stock (the "Warrants"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest. F4 · ownership.nature: (Footnote 3 Continue) Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F5 · ownership.nature: (Footnote 3 Continue)The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC |
Sawhney RogerDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003993 · ownership.xml · derivative · entry 1 Sawhney Roger · CIK 0001858748 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:37 UTC |
THOMSON TODD SDirector · 10% owner
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-004001 · ownership.xml · derivative · entry 1 THOMSON TODD S · CIK 0001225707 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F2 · kind: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4. F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. F2 · ownership.direct: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC |
Zabrowski DanDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003990 · ownership.xml · derivative · entry 1 Zabrowski Dan · CIK 0001940818 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC |
Keyes Jason ADirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003992 · ownership.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC |
Fletcher Aaron G.L.Director · 10% owner
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003988 · ownership.xml · derivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC |
RONNEBERG AMY LDirector
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003991 · ownership.xml · derivative · entry 1 RONNEBERG AMY L · CIK 0001380292 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:44 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,285 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002212 · ownership.xml · derivative · entry 2 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,285 Underlying: Common Stock · 204,285 shares Expires 2035-03-31 F2 · derivative.exercise_date: Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:44 UTC |
SCHMITT DANIEL MDirector · President, CEO and Director
|
GrantEmployee Stock Option (right to buy) · Derivative | 66,503 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002212 · ownership.xml · derivative · entry 1 SCHMITT DANIEL M · CIK 0001318470 · Director · President, CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,503 Underlying: Common Stock · 66,503 shares Expires 2035-03-31 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:43 UTC |
Mazar Andrew PaulChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 110,346 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002210 · ownership.xml · derivative · entry 2 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,346 Underlying: Common Stock · 110,346 shares Expires 2035-03-31 F2 · derivative.exercise_date: Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:43 UTC |
Mazar Andrew PaulChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 51,046 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002210 · ownership.xml · derivative · entry 1 Mazar Andrew Paul · CIK 0001727393 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,046 Underlying: Common Stock · 51,046 shares Expires 2035-03-31 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:41 UTC |
LYTLE PAUL JChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 41,899 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002208 · ownership.xml · derivative · entry 2 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,899 Underlying: Common Stock · 41,899 shares Expires 2035-03-31 F2 · derivative.exercise_date: Options will vest as to 25% on August 14, 2025 with the remaining 75% vesting in equal monthly installments during the 36 months thereafter. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 17:41 UTC |
LYTLE PAUL JChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 49,394 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001683168-25-002208 · ownership.xml · derivative · entry 1 LYTLE PAUL J · CIK 0001244110 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,394 Underlying: Common Stock · 49,394 shares Expires 2035-03-31 F1 · derivative.exercise_date: Options will vest as to 25% on April 1, 2026 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
OtherWarrant (Right to Buy) · Derivative | 3,528 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 55 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 3,528 shares Expires not disclosed F13 · derivative.exercise_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares. F13 · derivative.expiration_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
OtherWarrant (Right to Buy) · Derivative | 26,355 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 54 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 26,355 shares Expires not disclosed F12 · derivative.exercise_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares. F12 · derivative.expiration_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
OtherWarrant (Right to Buy) · Derivative | 8,068 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 53 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 8,068 shares Expires not disclosed F11 · derivative.exercise_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares. F11 · derivative.expiration_date: On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 573,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 52 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Actuate Co-Invest III, LP Disclosed balance after: 0 Underlying: Common Stock · 573,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.exercise_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.expiration_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 78,267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 51 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 Underlying: Common Stock · 78,267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.exercise_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.expiration_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 484,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 50 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 Underlying: Common Stock · 484,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.exercise_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.expiration_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 74,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 49 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 Underlying: Common Stock · 74,202 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · price: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.exercise_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F10 · derivative.expiration_date: Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative | 2,094,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 48 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Actuate Co-Invest II, LP Disclosed balance after: 0 Underlying: Common Stock · 2,094,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.exercise_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.expiration_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative | 326,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 47 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III NT, LP Disclosed balance after: 0 Underlying: Common Stock · 326,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.exercise_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.expiration_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative | 2,022,029 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 46 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III QP, LP Disclosed balance after: 0 Underlying: Common Stock · 2,022,029 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.exercise_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.expiration_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-4 Redeemable Convertible Preferred Stock · Derivative | 309,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 45 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund III, LP Disclosed balance after: 0 Underlying: Common Stock · 309,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · price: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.exercise_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F9 · derivative.expiration_date: Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative | 44,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 44 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II NT, LP Disclosed balance after: 0 Underlying: Common Stock · 44,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.exercise_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.expiration_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative | 332,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 43 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II QP, LP Disclosed balance after: 0 Underlying: Common Stock · 332,867 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.exercise_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.expiration_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-3 Redeemable Convertible Preferred Stock · Derivative | 101,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 42 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Fund II, LP Disclosed balance after: 0 Underlying: Common Stock · 101,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · price: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.exercise_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F8 · derivative.expiration_date: Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:49 UTC |
Fletcher Aaron G.L.Director · 10% owner
BIOS Capital Management, LPDirector · 10% owner
BIOS Advisors GP, LLCDirector · 10% owner
BIOS Fund III, LPDirector · 10% owner
BIOS Fund III QP, LPDirector · 10% owner
BIOS Fund III NT, LPDirector · 10% owner
BIOS Actuate Co-Invest I, LPDirector · 10% owner
BIOS Actuate Co-Invest II, LPDirector · 10% owner
Bios Actuate Co-Invest III, LPDirector · 10% owner
BIOS Equity Partners III, LPDirector · 10% owner
|
ConversionSeries B-2 Redeemable Convertible Preferred Stock · Derivative | 147,047 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-089822 · tm2421559-10_4seq1.xml · derivative · entry 41 Fletcher Aaron G.L. · CIK 0001789490 · Director · 10% owner BIOS Capital Management, LP · CIK 0001813845 · Director · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · Director · 10% owner BIOS Fund III, LP · CIK 0001791917 · Director · 10% owner BIOS Fund III QP, LP · CIK 0001791916 · Director · 10% owner BIOS Fund III NT, LP · CIK 0001791910 · Director · 10% owner BIOS Actuate Co-Invest I, LP · CIK 0001771378 · Director · 10% owner BIOS Actuate Co-Invest II, LP · CIK 0001825398 · Director · 10% owner Bios Actuate Co-Invest III, LP · CIK 0001956704 · Director · 10% owner BIOS Equity Partners III, LP · CIK 0001831976 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Directly held by Bios Actuate Co-Invest I, LP Disclosed balance after: 0 Underlying: Common Stock · 147,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date. F7 · price: Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date. F7 · derivative.exercise_date: Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date. F7 · derivative.expiration_date: Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest, LP ("Bios 2024 Co-Invest"). F3 · ownership.nature: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP. F4 · ownership.nature: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.